Dr Alan Griffith is Head of Global Operations at VectorBuilder. He has been working in CGT space for over a decade, he has raised ~50million in VC funding and angel investment over this time and worked across many functions in CGT.

Alan was the 5th employee at MeiraGTx (spin out from UCL, London and previously Athena Vision). He went on to help design and build London’s first subterranean, end to end multi vector, multi product GMP facility. He then worked at the first kidney-centric GT company, Purespring Tx as the Vice President of Research and led the team to select a novel AAV serotype/capsid and generated a novel kidney specific promoter as part of the clinical candidate selection process. He has been pivotal in enabling 5/6 clinical trials across 3 startups in 5 different disease areas. These products have all undergone extensive Process Development and manufacturing workflows and at various CMC scales (based on varying dose requirements per pathology).

In his career, he has held many senior positions such as Associate Director, Director, Vice President and Chief Development Officer (CDO) and has come full circle to work in the CDMO space, transitioning AAV products from preclinical to clinical, fulfilling his passion to aid emerging start-ups. Alan is keen to support VectorBuilders’ clients in avoiding some of the overlooked pitfalls in CMC, QC and Process development. He is an advisor for many industry groups and consults part time for developers and focus groups.
He holds various patents for AAV designs and route of administration approaches (promoters, capsids, GOIs, RoA) that confer competitive advantage and boost manufacturability at a scaled process. Alan not only has manufacturing experience but also served his time in quality control, which is central to the success of these complex and difficult to manufacture vectors. His experience helps give customised support to clients on their individual journeys and give patients the treatment they need and deserve.